- Page 1: Feverish illness in children: asses
- Page 5 and 6: Contents 1 Guideline summary 1 1.1
- Page 7 and 8: 1 Guideline summary 1.1 Guideline d
- Page 9 and 10: Guideline summary The GDG also cons
- Page 11 and 12: Figure 1.1 Care pathway for feveris
- Page 13 and 14: Guideline summary Number Recommenda
- Page 15 and 16: Guideline summary Number Recommenda
- Page 17 and 18: Guideline summary Number Recommenda
- Page 19 and 20: Guideline summary Number Recommenda
- Page 21 and 22: Guideline summary Number Recommenda
- Page 23 and 24: Guideline summary Number Recommenda
- Page 25 and 26: Guideline summary Number Recommenda
- Page 27 and 28: Guideline summary Number Recommenda
- Page 29 and 30: Guideline summary Number Research r
- Page 31 and 32: Guideline summary Number Research r
- Page 33 and 34: Introduction service, 34% of calls
- Page 35 and 36: Parental concern Introduction It is
- Page 37 and 38: 3 Guideline development methodology
- Page 39 and 40: Guideline development methodology (
- Page 41 and 42: Guideline development methodology T
- Page 43 and 44: Table 3.3 Levels of evidence for st
- Page 45 and 46: External review Guideline developme
- Page 47 and 48: Thermometers and the detection of f
- Page 49 and 50: Thermometers and the detection of f
- Page 51 and 52: Thermometers and the detection of f
- Page 53 and 54:
Thermometers and the detection of f
- Page 55 and 56:
5 Clinical assessment of children w
- Page 57 and 58:
Traffic light system Process used t
- Page 59 and 60:
Table 5.2 Traffic light system for
- Page 61 and 62:
Clinical assessment of the child wi
- Page 63 and 64:
Table 5.42 - evaluation of tenderne
- Page 65 and 66:
Number of studies 1 (Baker, 1989) N
- Page 67 and 68:
Clinical assessment of the child wi
- Page 69 and 70:
Table 5.9 GRADE profile for evaluat
- Page 71 and 72:
Number of studies Number of childre
- Page 73 and 74:
Number of studies Number of childre
- Page 75 and 76:
Table 5.20 GRADE profile for evalua
- Page 77 and 78:
Number of studies Number of childre
- Page 79 and 80:
Clinical assessment of the child wi
- Page 81 and 82:
Number of studies Number of childre
- Page 83 and 84:
Number of studies Number of childre
- Page 85 and 86:
Number of studies 1 (Stathakis, 200
- Page 87 and 88:
Table 5.30 GRADE profile for evalua
- Page 89 and 90:
Table 5.32 GRADE profile for evalua
- Page 91 and 92:
Table 5.34 GRADE profile for evalua
- Page 93 and 94:
Table 5.40 GRADE profile for evalua
- Page 95 and 96:
Table 5.46 GRADE profile for evalua
- Page 97 and 98:
Number of studies 1 (Teach, 1995) 1
- Page 99 and 100:
Weak, high-pitched or continuous cr
- Page 101 and 102:
Clinical assessment of the child wi
- Page 103 and 104:
Conjunctivitis (identified in 2013
- Page 105 and 106:
Clinical assessment of the child wi
- Page 107 and 108:
Clinical assessment of the child wi
- Page 109 and 110:
Clinical assessment of the child wi
- Page 111 and 112:
Other Fever for 5 days or more (inc
- Page 113 and 114:
Clinical assessment of the child wi
- Page 115 and 116:
Clinical assessment of the child wi
- Page 117 and 118:
Rigor and/or chills (identified in
- Page 119 and 120:
Heart rate Introduction Clinical as
- Page 121 and 122:
Clinical assessment of the child wi
- Page 123 and 124:
Clinical assessment of the child wi
- Page 125 and 126:
Table 5.57 GRADE findings for evalu
- Page 127 and 128:
Clinical assessment of the child wi
- Page 129 and 130:
Number of studies Number of childre
- Page 131 and 132:
Clinical assessment of the child wi
- Page 133 and 134:
Clinical assessment of the child wi
- Page 135 and 136:
Clinical assessment of the child wi
- Page 137 and 138:
Meningococcal disease Narrative evi
- Page 139 and 140:
GDG translation Clinical assessment
- Page 141 and 142:
Clinical assessment of the child wi
- Page 143 and 144:
[2007] Clinical assessment of the c
- Page 145 and 146:
Clinical assessment of the child wi
- Page 147 and 148:
6 Management by remote assessment I
- Page 149 and 150:
Management by remote assessment Th
- Page 151 and 152:
7 Management by the non-paediatric
- Page 153 and 154:
Management by the non-paediatric pr
- Page 155 and 156:
GDG translation Management by the n
- Page 157 and 158:
Recommendations Number Recommendati
- Page 159 and 160:
8 Management by the paediatric spec
- Page 161 and 162:
chest X-ray only if respiratory sig
- Page 163 and 164:
Management by the paediatric specia
- Page 165 and 166:
Management by the paediatric specia
- Page 167 and 168:
Number of studies Number of childre
- Page 169 and 170:
Table 8.2 GRADE findings for compar
- Page 171 and 172:
Number of studies Number of childre
- Page 173 and 174:
Number of studies Number of childre
- Page 175 and 176:
Management by the paediatric specia
- Page 177 and 178:
Evidence statements Management by t
- Page 179 and 180:
Management by the paediatric specia
- Page 181 and 182:
Viral co-infection Management by th
- Page 183 and 184:
Recommendations Number Recommendati
- Page 185 and 186:
Number of studies Torrey et al, 198
- Page 187 and 188:
hours. [new 2013] Number Research r
- Page 189 and 190:
Management by the paediatric specia
- Page 191 and 192:
Management by the paediatric specia
- Page 193 and 194:
Management by the paediatric specia
- Page 195 and 196:
Management by the paediatric specia
- Page 197 and 198:
Suspected meningococcal disease Man
- Page 199 and 200:
activity eating and drinking prev
- Page 201 and 202:
Number of studies 1 (Lesko et al.,
- Page 203 and 204:
Antipyretic interventions 9.2 Physi
- Page 205 and 206:
ibuprofen compared with paracetamol
- Page 207 and 208:
Number of studies Number of childre
- Page 209 and 210:
Number of studies Number of childre
- Page 211 and 212:
Number of studies Number of childre
- Page 213 and 214:
Number of studies Number of childre
- Page 215 and 216:
Number of studies Number of childre
- Page 217 and 218:
Number of studies Number of childre
- Page 219 and 220:
Number of studies Number of childre
- Page 221 and 222:
Number of studies Number of childre
- Page 223 and 224:
Antipyretic interventions Number of
- Page 225 and 226:
Table 9.6 GRADE findings for parace
- Page 227 and 228:
Antipyretic interventions AUC area
- Page 229 and 230:
Antipyretic interventions Number of
- Page 231 and 232:
Table 9.8 GRADE findings for ibupro
- Page 233 and 234:
Antipyretic interventions Number of
- Page 235 and 236:
Antipyretic interventions Number of
- Page 237 and 238:
Antipyretic interventions Two RCTs
- Page 239 and 240:
Antipyretic interventions There was
- Page 241 and 242:
10 Advice for home care Introductio
- Page 243 and 244:
Advice for home care As sufficient
- Page 245 and 246:
10.2 When to seek further help Advi
- Page 247 and 248:
Advice for home care been put to th
- Page 249 and 250:
Health economics at 3.5%. The analy
- Page 251 and 252:
Health economics Table 11.2 Compara
- Page 253 and 254:
Type of thermometer Singlemeasureme
- Page 255 and 256:
Total undiscounted 10-year cost (wi
- Page 257 and 258:
Health economics Figure 11.1 Decisi
- Page 259 and 260:
Health economics 11.4 Economic eval
- Page 261 and 262:
Table 11.10 Additional cost per add
- Page 263 and 264:
Health economics pathways for child
- Page 265 and 266:
Health economics symptom was noted.
- Page 267 and 268:
12 References References [2013] Akp
- Page 269 and 270:
Brewer et al.1968 References Brewer
- Page 271 and 272:
Hewson et al., 2000 References Hews
- Page 273 and 274:
Nahata et al., 1992 References Naha
- Page 275 and 276:
Stathakis et al., 2007 References S
- Page 277 and 278:
Weisse et al., 1987 References Weis
- Page 279 and 280:
References patients? The Evidence-B
- Page 281 and 282:
References 64. Dart RC, Lee SC, Joy
- Page 283 and 284:
References 106. Bonadio WA, Hennes
- Page 285 and 286:
References 148. Akinyoola AL, Obiaj
- Page 287 and 288:
188. Richardson AC, Roghmann KJ, Wh
- Page 289 and 290:
231. Andre P, Thebaud B, Guibert M,
- Page 291 and 292:
References 274. Wafula E, Tindybwa
- Page 293 and 294:
LRTI lower respiratory tract infect
- Page 295 and 296:
also double-blind study, single-bli
- Page 297 and 298:
Abbreviations and glossary may be q
- Page 299 and 300:
Abbreviations and glossary Dominanc
- Page 301 and 302:
Abbreviations and glossary Gold sta
- Page 303 and 304:
Abbreviations and glossary with bac
- Page 305 and 306:
Abbreviations and glossary Peer rev
- Page 307 and 308:
Randomised controlled trial (RCT) A
- Page 309 and 310:
Abbreviations and glossary Standard